94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
EDITORIAL article
Front. Cell. Infect. Microbiol.
Sec. Virus and Host
Volume 15 - 2025 | doi: 10.3389/fcimb.2025.1599910
This article is part of the Research Topic Papillomaviruses, immunity, and tumour development View all 9 articles
Editorial: Papillomaviruses, immunity, and tumour development
Provisionally accepted- 1 UK Health Security Agency, London, United Kingdom
- 2 University of Gothenburg, Gothenburg, Sweden
- 3 German Cancer Research Center (DKFZ), Heidelberg, Baden-Württemberg, Germany
The last decades have provided remarkable advances on the fight against HPV related diseases. 4Nevertheless, the scientific community remains engaged in advancing the current understanding 5 of mechanisms driving HPV pathogenesis and of key determinants of the HPV vaccine 6 effectiveness, which will assist with meeting the World Health Organization's Global Strategy for 7 cervical cancer elimination. In this Research Topic, we aimed to address the diversity and 8 complexity of the interplay between the three elements -HPV, immunity and cancer -and in 9 particular highlight the novelties and advances in the field, not least bringing into the spotlight 10 topics that may be underrepresented in papillomavirus research. 11Here, two works provide novel mechanistic evidence of host epithelium adaptation to high-risk 12HPV persistence and modulation of host immune responses by the beta-genus HPV E6 protein in 13 the inherited skin disorder epidermodysplasia verruciformis (EV). warranted, although such risks should be reduced in countries with high rates of HPV vaccine 83 coverage and particularly those that adopt gender neutral vaccination programmes. 84We would like to thank the researchers who have chosen to submit their works to this issue. 85
Keywords: Papillomaviruses, HPV, Immunity, Tumour development, Infection
Received: 25 Mar 2025; Accepted: 26 Mar 2025.
Copyright: © 2025 Beddows, Kann and Mariz. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Simon Beddows, UK Health Security Agency, London, United Kingdom
Hanna Kann, University of Gothenburg, Gothenburg, Sweden
Filipe Colaço Mariz, German Cancer Research Center (DKFZ), Heidelberg, 69120, Baden-Württemberg, Germany
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.